Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT) has released six-month preliminary data from the “Durasert and Vorolanib in Ophthalmology” phase 1 clinical study of EYP-1901 in wet related macular degeneration treatment.
The company presented the data at the 2021 American Academy of Opthalmology Annual Meeting Retina Subspecialty Day in New Orleans.
EYP-1901 shows a positive safety profile
CEO Nancy Lurker said, “We are very encouraged by these data that reinforce EYP-1901’s positive safety profile and its durable anti-VEGF activity up to six months so far in the majority of enrolled patients after a single intravitreal injection. Wet AMD is a leading cause of blindness, and these data bring us one step closer to potentially changing the standard of care for patients by offering an in-office sustained delivery treatment option with the potential for up to every six-month dosing.”
The Phase I DAVIO study was a dose-escalation study evaluating EYP-1901 in 17 wet AMD patients. Notably, EYP-1901 uses Eyepoint’s Durasert delivery tech
DAVIO Clinical Investigator David S. Boyer said, “We are grateful to the patients, investigators, and site staff who are participating in the DAVIO Phase 1 trial. We are very encouraged by today’s data results, which demonstrated the safety and sustained anti-VEGF activity of EYP-1901 in wet AMD patients Seeing treatment improvements for these patients is very promising, and we look forward to starting the next phase of this development program next year.”
The study included previously treated subjects
Eyepoint COO Jay S. Duker said, “Our clinical trial includes patients with previously treated wet AMD, who received frequent anti-VEGF injections prior to entering DAVIO. We were thrilled to see how well tolerated the EYP-1901 inserts appear to be and how well patients responded to EYP-1901 for both vision and anatomical endpoints over the six-month interim report of this 12-month study. These results are not only promising as we plan to move EYP-1901 into Phase 2 in wet AMD, but also for the potential to change the treatment paradigm for many wet AMD patients.”
